Why the study?
Does immunization with recombinant HAV-HEp148 virus induce an immune response against HAV and HEV in mice?
Does immunization with recombinant HAV-HEp148 virus induce an immune response against HAV and HEV in mice?
A recombinant HAV expressing an HEV neutralization epitope successfully induces immune responses against both viruses in mice, suggesting potential as a combined vaccine.
Hepatitis A virus (HAV) and hepatitis E virus (HEV) are causative agents of acute viral hepatitis transmitted via the fecal-oral route. Both viruses place a heavy burden on the public health and economy of developing countries. To test the possibility that HAV could be used as an expression vector for the development of a combination vaccine against hepatitis A and E infections, recombinant HAV-HEp148 was created as a vector to express an HEV neutralization epitope (HEp148) located at aa 459-606 of the HEV capsid protein. The recombinant virus expressed the HEp148 protein in a partially dimerized state in HAV-susceptible cells. Immunization with the HAV-HEp148 virus induced a strong HAV- and HEV-specific immune response in mice. Thus, the present study demonstrates a novel approach to the development of a combined hepatitis A and E vaccine.
No takes yet. Share an insight, caveat, or question.
Xiang et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: